Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias.
Característiques principals
FUNDING MECHANISMS:
  • Drug Development RFP: The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.
  • Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
  • Prevention Pipeline RFP: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
  • Lloc de presentació
    IMIM and PSMAR staff who need more information should contact::
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    https://www.alzdiscovery.org/research-and-grants/funding-opportunities
    Requisits
    Funding is open to researchers and clinicians worldwide at
  • Academic medical centers and universities or nonprofits. Industry partnerships are encouraged
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • Dotació
  • Drug development: Up to $5,000,000 based on stage and scope of research.
  • Neuroimaging and CSF biomarker development program: up to $600,000
  • Prevention pipeline: Up to $5,000,000 for clinical trials based on stage and scope of research
  • Durada
  • Applications are reviewed throughout the year. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.
  • AVÍS IMPORTANT
    Deadlines for 2024 RFPs:
    LETTERS OF INTENT:
  • February 5, 2024
  • May 13, 2024
  • September 30, 2024

    INVITED FULL PROPOSALS:
  • April 8, 2024
  • July 22, 2024
  • December 9, 2024
  • Arxius

    Arxiu
    Drug Development RFP _ Alzheimer's Drug Discovery Foundation.pdf
    Neuroimaging and CSF Biomarker Program _ Alzheimer's Drug Discovery Foundation.pdf
    Prevention _ Alzheimer's Drug Discovery Foundation.pdf
    Application Instructions _ Alzheimer's Drug Discovery Foundation full.pdf
    Application Instructions _ Alzheimer's Drug Discovery Foundation.pdf